AUPHAurinia Pharmaceuticals Inc.
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and typical volatility.
Insiders were net sellers (-$546K, 90 days to Oct 8, 2026), selling is often routine.
Moderate price swings, typical volatility. Worst drawdown -88% · now 11% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AUPH take a bad year?
The deepest fall in AUPH's price history on file is −88%; it is 11% below its high today.
Worst drawdown on file · −11% today
- Interest cover
- 36.7×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 43%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $180M
- EBITDA, trailing twelve months
- $161M
- Operating profit, trailing twelve months
- $151M
- Annualised volatilitytwo years of daily moves
- 43%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 11%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.